This database contains 231 studies, archived under the term: "ADLs/IADLs"
Click here to filter this large number of results.
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M.,
Bell, K. L.,
Galasko, D.,
Galvin, J. E.,
Thomas, R. G.,
van Dyck, C. H.,
Aisen, P. S.
Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, […]
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S.,
Sperling, R.,
Keren, R.,
Porsteinsson, A. P.,
van Dyck, C. H.,
Tariot, P. N.,
Gilman, S.,
Arnold, D.,
Abushakra, S.,
Hernandez, C.,
Crans, G.,
Liang, E.,
Quinn, G.,
Bairu, M.,
Pastrak, A.,
Cedarbaum, J. M.
Objective: This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD).; Methods: A total of 353 patients were randomized to ELND005 (250, 1,000, or 2,000 mg) or placebo twice daily for 78 weeks. Coprimary endpoints were the […]
Effectiveness of nonpharmacological approaches in patients with mild cognitive impairment
Tsolaki, Magda,
Kounti, Fotini,
Agogiatou, Christina,
Poptsi, Eleni,
Bakoglidou, Evangelia,
Zafeiropoulou, Myrto,
Soumbourou, Aikaterini,
Nikolaidou, Evdokia,
Batsila, Georgia,
Siambani, Aikaterini,
Nakou, Stella,
Mouzakidis, Christos,
Tsiakiri, Anna,
Zafeiropoulos, Stavros,
Karagiozi, Konstantina,
Messini, Chaido,
Diamantidou, Alexandra,
Vasiloglou, Maria
Background: Mild cognitive impairment (MCI) patients are at increased risk of developing dementia. There is a conflict if cognitive interventions can improve cognitive and functional performances in order to delay the development of dementia.; Objectives: This study aimed to examine the effectiveness of a holistic cognitive rehabilitation program on patients with MCI.; Methods: The participants, […]
Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer’s disease: results of a 16-week open-label trial
Schulz, Jörg B.,
Rainer, Michael,
Klünemann, Hans-Hermann,
Kurz, Alexander,
Wolf, Stefanie,
Sternberg, Kati,
Tennigkeit, Frank
The present study evaluated the effects of once-daily memantine (20 mg) treatment on cognition and communication in patients with moderate to severe Alzheimer’s disease (AD). In a multicenter, single-arm open-label study, outpatients diagnosed with AD (MMSE < 20; n = 97) were titrated from 5 mg to 20 mg once-daily memantine over 4 weeks. Once-daily […]
Health and nutrition promotion program for patients with dementia (NutriAlz): cluster randomized trial
Salva, A.,
Andrieu, S.,
Fernandez, E.,
Schiffrin, E. J.,
Moulin, J.,
Decarli, B.,
Rojano-i-Luque, X.,
Guigoz, Y.,
Vellas, B.
Objective: To assess the effectiveness of health and nutrition program (NutriAlz) versus usual care on functional level in elderly people with dementia living at home, as well as on clinical practice related to nutrition and on the caregiver’s burden.; Design: Cluster randomized multi-centre study with one-year follow-up.; Setting: 11 Alzheimer outpatients and day care centres […]
A phase II trial of huperzine A in mild to moderate Alzheimer disease
Rafii, M. S.,
Walsh, S.,
Little, J. T.,
Behan, K.,
Reynolds, B.,
Ward, C.,
Jin, S.,
Thomas, R.,
Aisen, P. S.
Objective: Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata that may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use for Alzheimer disease (AD).; Methods: We assessed the safety, tolerability, and efficacy of huperzine A in mild to moderate AD in a multicenter trial in which 210 […]
Donepezil treatment in Alzheimer’s disease patients with and without cerebrovascular lesions: a preliminary report
Na, Hae-Ri,
Kim, SangYun,
Choi, Seong Hye,
Yang, Dong-Won,
Bae, Hee-Joon,
Kim, Jung-Eun,
Park, Mee-Young,
Shim, Yong-Soo,
Kim, Byung-Kun,
Kwon, Jae-Cheol,
Yoo, Bong Goo,
Kim, Byeong-Chae,
Lee, Jung-Seok
Aim: Donepezil has not been evaluated in Korean patients with Alzheimer’s disease (AD) for up to 1 year. The objectives of this study were to evaluate the differential efficacy of donepezil in Korean AD patients with and without concomitant cerebrovascular lesions (CVL).; Methods: This study was a 48-week open-label trial of donepezil in patients with […]
Study protocol for the recreational stimulation for elders as a vehicle to resolve delirium superimposed on dementia (Reserve For DSD) trial
Kolanowski, Ann M.,
Fick, Donna M.,
Litaker, Mark S.,
Clare, Linda,
Leslie, Doug,
Boustani, Malaz
Background: Delirium is a state of confusion characterized by an acute and fluctuating decline in cognitive functioning. Delirium is common and deadly in older adults with dementia, and is often referred to as delirium superimposed on dementia, or DSD. Interventions that treat DSD are not well-developed because the mechanisms involved in its etiology are not […]
Pilot study of a nonpharmacological intervention for delirium superimposed on dementia
Kolanowski, Ann M.,
Fick, Donna M.,
Clare, Linda,
Steis, Melinda,
Boustani, Malaz,
Litaker, Mark
Delirium is a common neuropsychiatric syndrome that occurs most frequently in older adults with dementia and is referred to as delirium superimposed on dementia (DSD). Our aim in this pilot project was to demonstrate that implementation of cognitively stimulating activities is clinically feasible and has potential to reduce delirium severity and duration and functional loss […]